- Home
- CNTA vs CSQ Comparison
CNTA vs CSQ Comparison
Compare CNTA & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$25.65
Company Overview
Basic Information| Metric | CNTA | CSQ |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTA | CSQ |
|---|---|---|
| Price | $25.65 | $19.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 220.3K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 118.88 | N/A |
| 52 Week Low | $9.60 | $12.50 |
| 52 Week High | $30.58 | $16.45 |
Technical Indicators
Market Signals| Indicator | CNTA | CSQ |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 53.07 |
| Support Level | $21.50 | $19.27 |
| Resistance Level | $26.63 | $19.46 |
| Average True Range (ATR) | 1.13 | 0.21 |
| MACD | 0.52 | -0.02 |
| Stochastic Oscillator | 81.48 | 51.20 |
Price Performance
Historical Comparison CNTA
CSQ
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.